



BeiGene Establishes Initial Climate Goal, Strengthening Commitment to Responsible Business and Sustainability

On December 18, 2023, BeiGene, Ltd (“the company”) announced a new climate goal reflecting its strengthened commitment to energy efficiency programs and sustainable business planning to deliver long term value. The target established is to reduce the carbon intensity of its Scope 1 and Scope 2 greenhouse gas (GHG) emissions by 25% per unit of product by 2026 from a 2021 baseline.

This represents the company’s first quantitative environmental target since it began reporting its global GHG emissions in 2022. BeiGene plans to achieve this target primarily through the implementation of energy efficiency projects identified in several key facilities, which are projected to provide both energy as well as cost savings for the organization as it continues to grow. This goal also fulfills the commitment communicated earlier this year to set a quantitative emissions goal by 2024 and reflects the company’s commitment to environmental sustainability as it continues to plan for growth of its two global cornerstone medicines and high-value oncology pipeline. BeiGene remains on track to set a quantitative Scope 3 target by 2025, addressing emissions from third parties throughout its value chain.

Change is the Cure

BeiGene’s Responsible Business and Sustainability strategy, Change is the Cure, is centered around five pillars: advancing global health, empowering our people, innovating sustainably, supporting communities and operating responsibly. BeiGene has committed to setting goals for each of these pillars and reporting on progress. For more information about BeiGene’s Change Is the Cure strategy, achievements and goals, please download a copy of the most recent report [here](#).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s commitment to energy efficiency programs and sustainable business planning; the ultimate energy and cost savings that may result from BeiGene’s sustainability projects; the value of BeiGene’s oncology pipeline; BeiGene’s ability to deliver sustainable long-term value to stakeholders; and BeiGene’s plans, commitments, aspirations, and goals under the headings “Change is the Cure” and “About BeiGene.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to reduce its GHG emissions by the targeted amount or any amount at all; BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing, and other services; and BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates and achieve and maintain profitability, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.